1. Home
  2. CINGW vs SLF Comparison

CINGW vs SLF Comparison

Compare CINGW & SLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • SLF
  • Stock Information
  • Founded
  • CINGW N/A
  • SLF 1871
  • Country
  • CINGW United States
  • SLF Canada
  • Employees
  • CINGW 13
  • SLF N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • SLF Advertising
  • Sector
  • CINGW Health Care
  • SLF Consumer Discretionary
  • Exchange
  • CINGW Nasdaq
  • SLF Nasdaq
  • Market Cap
  • CINGW N/A
  • SLF N/A
  • IPO Year
  • CINGW 2021
  • SLF N/A
  • Fundamental
  • Price
  • CINGW $0.04
  • SLF $54.61
  • Analyst Decision
  • CINGW
  • SLF
  • Analyst Count
  • CINGW 0
  • SLF 0
  • Target Price
  • CINGW N/A
  • SLF N/A
  • AVG Volume (30 Days)
  • CINGW N/A
  • SLF 773.2K
  • Earning Date
  • CINGW N/A
  • SLF 02-12-2025
  • Dividend Yield
  • CINGW N/A
  • SLF 4.35%
  • EPS Growth
  • CINGW N/A
  • SLF N/A
  • EPS
  • CINGW N/A
  • SLF 3.65
  • Revenue
  • CINGW N/A
  • SLF $23,006,727,641.00
  • Revenue This Year
  • CINGW N/A
  • SLF N/A
  • Revenue Next Year
  • CINGW N/A
  • SLF $2.46
  • P/E Ratio
  • CINGW N/A
  • SLF $14.79
  • Revenue Growth
  • CINGW N/A
  • SLF 7.30
  • 52 Week Low
  • CINGW N/A
  • SLF $46.41
  • 52 Week High
  • CINGW N/A
  • SLF $62.85
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • SLF 32.65
  • Support Level
  • CINGW N/A
  • SLF $53.57
  • Resistance Level
  • CINGW N/A
  • SLF $56.11
  • Average True Range (ATR)
  • CINGW 0.00
  • SLF 1.18
  • MACD
  • CINGW 0.00
  • SLF -0.33
  • Stochastic Oscillator
  • CINGW 0.00
  • SLF 17.75

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: